论文部分内容阅读
目的:研究软肝散结胶囊对大鼠肝纤维化的防治作用。方法:选用雄性大鼠,随机分为正常对照、模型组、给药30 g·kg-1组和给药15 g·kg-1组。除正常对照组外,肝纤维化模型用4O%四氯化碳油液首次5 mL·kg-1以后每次3mL·kg-1sc,每周2次,连续8周。造模首日给药组开始给药,连续8周后麻醉大鼠,腹腔主动脉取血,测定血清AST,ALT,总蛋白(Tb),白蛋白(ALb)含量;取肝制备10%肝匀浆,测定其丙二醛(MDA)、超氧化物歧化酶(SOD)和羟脯氨酸(HYP)水平。结果:大鼠肝纤维化损伤时,血清ALT,AST活性升高,肝匀浆MDA和肝组织HYP明显增加.Tb,ALb,肝组织SOD活性降低。软肝散结胶囊给药组与模型组比较可降低ALT,AST活性及肝匀浆HYP水平,而提高血清ALB,TB及肝组织SOD活性。结论:软肝散结胶囊对四氯化碳实验性大鼠肝纤维化具有防治作用。
Objective: To study the preventive and therapeutic effects of Ruangan Sanjie capsule on hepatic fibrosis in rats. Methods: Male rats were randomly divided into normal control group, model group, administration of 30 g · kg-1 group and administration of 15 g · kg-1 group. In addition to the normal control group, the liver fibrosis model with 4O% carbon tetrachloride oil for the first 5 mL · kg-1 after each 3mL · kg-1sc twice a week for 8 weeks. The rats in the first administration on the first day of the model were given medicine. After 8 consecutive weeks, the rats were anesthetized and the abdominal aorta blood was taken for determination of serum AST, ALT, total protein (Tb) and albumin (ALb) The contents of malondialdehyde (MDA), superoxide dismutase (SOD) and hydroxyproline (HYP) were measured. Results: After liver fibrosis, the activity of ALT and AST in serum increased, MDA in liver homogenate and HYP in hepatic tissue increased obviously, SOD activity in Tb, ALb and liver decreased. Compared with the model group, the administration of Ruangansanjie Capsule reduced ALT and AST activity and liver homogenate HYP level, but increased serum ALB, TB and liver SOD activity. Conclusion: Rugan Sanjie Capsule has protective effects on hepatic fibrosis induced by carbon tetrachloride in rats.